AI OKTO Corp., a global energy transportation ship-owner, announced a special dividend of $3.50 per share payable either in cash or common shares. The dividend is for shareholders of record as of November 2, 2026, with payment expected around November 25, 2026. Shareholders can elect to receive the dividend in cash or shares based on a 5-day average price, but the company may opt to pay all in cash. Due to the dividend size exceeding 25% of the share price, Nasdaq will apply "due bills" trading rules during the dividend period, affecting dividend rights for buyers and sellers of shares.
AI OKTO Corp.'s special dividend announcement is presented here with Pluang's Energy sector market data as of Oct 23, 2026 19:31 WIB. Among 79 priced Energy-sector US stocks tradable on Pluang, 55 rose and 19 fell today. Notable movers include UGP at USD 7.98 with a 1-day change of +2.31% and a typical hold time of 9 days, WMB at USD 72.15 with a 1-day change of +2.15% and a typical hold time of 58 days, and SU at USD 79.00 with a 1-day change of +2.05% and a typical hold time of 57 days. The most notable figure is UGP's 9-day typical hold time on Pluang.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
